Clinical Trial Update: An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) [Phase 4]

View source ↗

Summary

An open-label Phase 4 trial assessing the immunogenicity of the liquid formulation of Saizen in adults with Adult Growth Hormone Deficiency; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Saizen (somatropin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Adult Growth Hormone Deficiency | Phase 4 | Status: COMPLETED | Results posted: 2017-04-04